On June 23, 2021, the National Medical Products Administration (NMPA) announced the conditional approval of Savolitinib Tablets (trade name: ORPATHYS), a Class 1 innovative drug developed and submitted by Hutchison China MediTech (Shanghai) Co., Ltd., through the priority review and approval process.
This is an innovative drug with independent intellectual property rights in China.
It is indicated for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition factor (MET) exon 14 skipping alterations, whose disease has progressed after platinum-based chemotherapy or who are intolerant to standard platinum-based chemotherapy.
About Savolitinib
Savolitinib can selectively inhibit the phosphorylation of the MET kinase, exerting a significant inhibitory effect on the proliferation of tumor cells with MET exon 14 skipping alterations.
As the first small-molecule inhibitor specifically targeting the MET kinase approved in China, its launch provides a novel treatment option for patients with advanced NSCLC harboring MET exon 14 skipping alterations.
